Asarina Pharma AB (publ) Q2 2022 Report released
CEO Peter Nordkild: “We are pleased to report continued progress in our Phase II study in Sepranolone for the treatment of Tourette in the second quarter of 2022. With more than two thirds of patients recruited and a drop-out rate of under 5%, the study remains fully funded, and we remain confident of reporting topline results by the end of Q1 2023.”
FINANCIAL HIGHLIGHTS
- Total operating costs have been further reduced to SEK 4.0 million (Q2/2021: SEK 16.0 million.) This reflects that all resources are now being allocated to our phase IIa study in Tourette
- Present funding still expected to cover the remaining cost of the Tourette study
R&D HIGHLIGHTS
TOURETTE SYNDROME
- 70 % of patients have been recruited onto the Tourette study at two sites in Copenhagen
- The dropout rate so far is unexpectedly low, at under 5%. To date no patients have dropped out from our largest ‘active dose’ group of those patients taking Sepranolone in addition to their regular treatment
- During summer 2022 we recruited our first teenage patients (at the Danish National Center for Tourette at Herlev University Hospital)
- Last-patient-last-visit remains scheduled for January 2023
- Topline results to be released by the end of Q1 2023
CEO Peter Nordkild: “If full clinical development is successful, Sepranolone will be the first endogenous, neuroendocrinological compound used to treat Tourette. As such it would represent an entirely new treatment modality - with no serious side effects. We would like to thank the ongoing commitment of our volunteer patients and our excellent teams at Bispebjerg and Herlev University hospitals in Copenhagen.”
To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/
